EL7.AI
StocksMedium•3 August 2026•
1 min read

Palantir Raises Annual Revenue Forecast on Surging Data Software Demand

Key Facts

1Palantir Technologies raised its annual revenue forecast again, signaling strong demand for its data analytics software from government and commercial clients.
2Vertex Pharmaceuticals raised its annual revenue forecast driven by the strength of its cystic fibrosis drugs.

Palantir Technologies has raised its annual revenue forecast for the second time, signaling robust demand for its data analytics software from both government and commercial clients. This upward revision is driven by high demand for the company's AI and data platforms, particularly within the US market. Similarly, Vertex Pharmaceuticals also increased its full-year guidance, supported by strong sales performance in its specialized drug portfolio.

Per market data, PLTR shares closed at $123.06 (close July 31, 2026), having traded between a day low of $119.62 and a high of $123.39. The simultaneous guidance hikes from growth-oriented firms like Palantir and Vertex suggest a resilient demand environment for high-end technology and biotech innovations, even as broader market conditions remain under scrutiny.

Investors are watching for PLTR to maintain levels above the $119.62 support established at the end of July. With the Federal Reserve recently holding interest rates at 3.75% as of July 29, 2026, the focus for retail traders remains on whether these raised revenue targets will translate into sustained momentum for high-growth tech stocks in the coming weeks.